



Regd.Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Telangana, India, 500081
Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com
D.L.No.TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB

To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 14.11.2024

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting for the quarter 30.09.2024 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Thursday, the 14th day of November, 2024 at 05.00 P.M. at registered office of the Company, inter alia approved the following items of business:

1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter and half year ended 30th September 2024. (Enclosed as **Annexure I**).
2. Limited Review Report (Standalone and Consolidated) for the Quarter and half year ended 30th September 2024. (Enclosed as **Annexure II**).

The meeting concluded at 06:15 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully

For Decipher Labs Limited

**SUSHANT
MOHAN
LAL**

Digitally signed by SUSHANT MOHAN LAL, DN: cn=SUSHANT MOHAN LAL, o=DECIPHER LABS LIMITED, ou=DECIPHER LABS LIMITED, email=SUSHANT.MOHAN.LAL@DECIPHERLABSLIMITED.COM, c=IN

Sushant Mohan Lal
Executive Director
(DIN: 01227151)

Encl. as above

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd. off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Unaudited Standalone Financial Results For the Quarter and Half Year Ended 30th September, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	8.38	38.34	-	46.72	-	353.16
II. Other income	1.77	0.17	0.50	1.94	1.00	1.99
III. Total Income (I + II)	10.15	38.51	0.50	48.66	1.00	355.14
IV. Expenses						
Purchase of Stock in trade	-	29.25	-	29.25	-	313.77
Changes in inventories of stock in trade	-	-	-	-	-	-
Employee Benefits Expense	4.40	7.72	4.25	12.12	8.50	16.99
Finance Costs	-	-	-	-	-	-
Depreciation expense	0.45	0.32	0.37	0.77	0.73	1.45
Other expenses	11.05	13.83	4.89	24.88	11.33	20.42
Total expenses	15.89	51.12	9.51	67.01	20.56	352.63
V. Profit/(Loss) before Exceptional items (III - IV)	(5.74)	(12.61)	(9.02)	(18.34)	(19.57)	2.51
VI. Exceptional items						
VII. Profit/(Loss) after Exceptional items (V - VI)	(5.74)	(12.61)	(9.02)	(18.34)	(19.57)	2.51
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.11)	0.47	(1.54)	0.36	0.13	(0.18)
IX. Profit/(Loss) for the period (VII-VIII)	(5.63)	(13.08)	(7.48)	(18.70)	(19.70)	2.33
X. Other comprehensive income	-	-	-	-	-	-
XI. Total comprehensive income for the year	(5.63)	(13.08)	(7.48)	(18.70)	(19.70)	2.33
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share						
(1) Basic	(0.06)	(0.13)	(0.07)	(0.19)	(0.20)	0.02
(2) Diluted	(0.06)	(0.13)	(0.07)	(0.19)	(0.20)	0.02

Notes

1. The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Half Year Ended		Year Ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	-	30.00	-	30.00	52.02	327.33
b) Consultancy Services	8.38	8.34	-	16.72	16.04	25.83
Total Sales	8.38	38.34	-	46.72	68.06	353.16
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	8.38	38.34	-	46.72	68.06	353.16
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(1.92)	(9.87)	(9.02)	(11.79)	(4.46)	2.33
b) Consultancy Services	(3.83)	(2.74)	-	(6.57)	(1.38)	0.18
Total	(5.74)	(12.61)	(9.02)	(18.35)	(5.84)	2.52
Less: Interest and exceptional items	-	-	-	-	-	-
Total Profit before tax	(5.74)	(12.61)	(9.02)	(18.35)	(5.84)	2.52
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	893.52	900.13	885.75	893.52	919.19	1,267.85
b) Consultancy Services	16.73	8.34	-	16.73	12.83	8.25
Total Assets	910.25	908.47	885.75	910.25	932.02	1,276.10
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	20.30	28.79	15.02	20.30	8.97	383.34
b) Consultancy Services	-	-	-	-	-	-
c) Unallocated liabilities	-	-	-	-	0.37	-
Total Liabilities	20.30	28.79	15.02	20.30	9.35	383.34

2. The above results for the half year ended 30th September 2024 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th November 2024.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

For and on behalf of the Board



Sushant Mohan Lal

Sushant Mohan Lal
Executive whole time director
DIN: 01227151

Place: Hyderabad
Date: 14.11.2024

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781) Regd. off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151 Standalone statement of Assets and Liabilities as on 30 September 2024		
Rs. in Lakhs		
Particulars	As at 30th September 2024	As at 31st March 2024
	Unaudited	Audited
I. ASSETS		
Non-current assets		
(a) Property Plant and Equipment	14.70	10.43
(b) Financial assets		
Investments	866.41	866.41
(c) Other non-current assets	3.50	0.30
(d) Deferred Tax Assets	1.45	1.81
Current assets		
(a) Financial assets		
(i) Trade receivables	16.73	394.50
(ii) Cash and cash equivalents	1.53	2.65
(b) Current tax assets	0.23	-
(c) Other current assets	5.70	-
TOTAL ASSETS	910.25	1,276.10
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	(135.95)	(117.24)
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	15.91	-
(ii) Trade payables		
a) Total outstanding dues of Micro and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro and small enterprises	7.43	369.64
(iii) Other financial liabilities	12.64	13.23
(b) Other current liabilities	0.23	0.48
TOTAL EQUITY AND LIABILITIES	910.25	1,276.10

Place: Hyderabad
Date: 14.11.2024



For and on behalf of the Board

Sushant Mohan Lal

Sushant Mohan Lal
Executive whole time director
DIN: 01227151

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)				
Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081				
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151				
Standalone Statement of Cash Flows for the Half Year Ended 30th September 2024				
All amounts in ₹ Lakhs, unless otherwise stated				
Particulars	Year ended 30th September, 2024 (Unaudited)		Year ended 31st March, 2024 (Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(18.35)		2.51
Adjustments for:				
Depreciation		0.77		1.45
Loss on sale of asset		(0.36)		-
Operating Profit before Working Capital Changes		(17.95)		3.96
Adjustments for:				
(Increase) / Decrease in Trade Receivables	377.76		(381.75)	
(Increase) / Decrease in Inventories	-		-	
(Increase) / Decrease in Other Assets	(5.93)		0.03	
(Increase) / Decrease in Other Non Current Assets	(3.20)		-	
Increase / (Decrease) in Trade Payable	(362.21)		369.64	
Increase / (Decrease) in Other Liabilities	15.07		5.16	
		21.49		(6.93)
Cash Generated from Operations		3.54		(2.97)
Direct Taxes Paid		-		-
Net Cash generated from/(used in) Operating Activities		3.54		(2.97)
B. CASH FLOW FROM INVESTING ACTIVITIES				
Sale of Fixed Asset	1.01		-	
Purchase of Fixed Asset	(5.69)		-	
Net Cash used in Investing Activities		(4.67)		-
C. CASH FLOW FROM FINANCING ACTIVITIES				
Net decrease in Cash and Cash Equivalents		(1.13)		(2.97)
Cash and Cash Equivalents at the beginning of the year		2.65		5.62
Cash and Cash Equivalents at the end of the period		1.53		2.65



For and on behalf of the Board

Sushant Mohan Lal

Sushant Mohan Lal
Executive whole time director
DIN: 01227151

Place: Hyderabad
Date: 14.11.2024

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd. off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Unaudited Consolidated Financial Results For the Quarter and Half Year Ended September 30, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	586.67	744.10	749.24	1,330.77	1,700.11	3,587.85
II. Other income	12.09	15.81	13.79	27.90	14.29	41.65
III. Total revenue (I + II)	598.76	759.91	763.03	1,358.67	1,714.40	3,629.51
IV. Expenses						
Purchase of Stock-in-Trade	-	29.25	-	29.25	-	313.77
Changes in inventories of finished goods and stock in trade	-	-	-	-	-	-
Employee benefits expense	668.72	511.35	777.92	1,180.07	1,582.75	2,774.94
Finance costs	-	-	-	-	0.52	21.76
Depreciation and amortisation expense	11.50	11.28	11.28	22.78	22.43	45.27
Other expenses	51.28	72.24	187.71	123.52	347.50	594.88
Total expenses	731.50	624.12	976.91	1,355.62	1,953.20	3,750.62
V. Profit/(Loss) before Exceptional item (III - IV)	(132.74)	135.80	(213.88)	3.05	(238.80)	(121.11)
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) before tax (III - IV)	(132.74)	135.80	(213.88)	3.05	(238.80)	(121.11)
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	0.06	41.13	(19.60)	41.19	50.29	46.45
IX. Profit/(Loss) for the period (V-VI)	(132.80)	94.66	(194.28)	(38.14)	(289.09)	(167.56)
X. Other comprehensive income						
Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	28.26	(0.24)	11.92	28.02	14.15	32.77
XI. Total comprehensive income for the year	(104.54)	94.42	(182.36)	(10.12)	(274.94)	(134.79)
Net Profit/(Loss) for the year attributable to:						
Owners of the parent	(38.14)	94.66	(194.28)	(38.14)	(289.09)	(167.56)
Non-Controlling Interests	-	-	-	-	-	-
Other Comprehensive Income attributable to:						
Owners of the parent	(104.54)	94.42	(182.36)	(10.12)	(274.94)	(134.79)
Non-Controlling Interests	-	-	-	-	-	-
Total Comprehensive Income attributable to:						
Owners of the parent	(104.54)	94.42	(182.36)	(10.12)	(274.94)	(134.79)
Non-Controlling Interests	-	-	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share						
(1) Basic	(1.31)	0.94	(1.92)	(0.38)	(2.86)	(1.66)
(2) Diluted	(1.31)	0.94	(1.92)	(0.38)	(2.86)	(1.66)

Notes

1. The operations of the Group relate to two segments viz.; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	-	30.00	-	30.00	-	327.33
b) Consultancy Services	586.67	714.10	749.24	1,300.77	1,700.11	3,260.53
Total Sales	586.67	744.10	749.24	1,330.77	1,700.11	3,587.86
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	586.67	744.10	749.24	1,330.77	1,700.11	3,587.86
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(17.35)	5.47	(9.02)	(11.88)	(19.57)	(9.06)
b) Consultancy Services	(115.40)	130.32	(233.60)	14.92	(218.71)	(90.29)
Total	(132.74)	135.80	(242.62)	3.05	(238.28)	(99.35)
Less: Interest and exceptional item	-	-	-	-	0.52	21.76
Total Profit/(Loss) before tax	(132.74)	135.80	(242.62)	3.05	(238.80)	(121.11)
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	55.40	900.47	45.89	55.40	45.89	427.85
b) Consultancy Services	3,001.36	2,207.76	2,347.31	3,001.36	2,347.31	2,935.46
Total Assets	3,056.76	3,108.22	2,393.20	3,056.76	2,393.20	3,363.31
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	21.43	28.79	15.02	21.43	15.02	383.34
b) Consultancy Services	882.72	798.93	318.11	882.72	318.11	793.91

Total Liabilities	904.15	827.72	333.13	904.15	333.13	1,177.25
--------------------------	---------------	---------------	---------------	---------------	---------------	-----------------

2. The above results for the quarter and half year ended 30 September 2024 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th November 2024.
3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
4. The above results as of 30 September 2024 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.



For and on behalf of the Board

A handwritten signature in blue ink, appearing to read "Sushant Mohan Lal".

Sushant Mohan Lal
Executive whole time director
DIN: 01227151

Place: Hyderabad
Date: 14.11.2024

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151 Consolidated Statement of Assets and Liabilities as on 30th September 2024 All amounts in ₹ Lakhs, unless otherwise stated		
Particulars	As at 30th September, 2024 (Unaudited)	As at 31st March, 2024 (Audited)
I. ASSETS		
Non-current Assets		
(a) Property, Plant and Equipment	87.96	88.00
(b) Investment	235.96	338.93
(c) Deferred tax asset (net)	14.73	55.64
(d) Goodwill	186.03	202.63
(e) Other non current assets	333.53	210.31
Current Assets		
(a) Financial assets		
(i) Trade receivables	517.89	779.84
(ii) Cash and cash equivalents	493.48	931.38
(iii) Other Financial Asset	3.24	96.51
(b) Other current assets	1,183.94	660.08
TOTAL ASSETS	3,056.76	3,363.31
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	1,142.61	1,176.06
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	15.91	-
(ii) Trade payables		
a) Total outstanding dues of Micro enterprises and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	159.16	499.38
(iii) Other Financial liabilities	728.85	677.41
(b) Other current liabilities	0.23	0.46
TOTAL EQUITY AND LIABILITIES	3,056.76	3,363.31

For and on behalf of the Board



Sushant Mohan Lal

Sushant Mohan Lal
Executive whole time director
DIN: 01227151

Place: Hyderabad
Date: 14.11.2024

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Half Year Ended 30th September, 2024 (Unaudited)	Year Ended 31st March, 2024 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax	3.05	(121.11)
Adjustments for :		
Exchange differences on translating the financial statements of a foreign operation	4.68	32.77
Depreciation and amortisation expense	22.78	45.27
Finance costs	-	21.76
Loss on sale of asset	-	-
Balances written off	-	-
PPP loan written off	-	-
Operating Profit before Working Capital Changes		
Changes in operating assets and liabilities		
(Increase) / Decrease in Trade Receivables	261.37	205.59
(Increase) / Decrease in Other Assets	(553.81)	(475.45)
Increase / (Decrease) in Trade Payable	(340.22)	379.24
Increase / (Decrease) in Other Liabilities	51.21	397.35
Cash Generated from Operations	(550.94)	485.42
Income taxes paid	-	-
Net cash inflow (outflow) from operating activities	(550.94)	485.42
Cash flows from investing activities		
Purchase of Fixed assets including Capital WIP	(5.84)	(5.84)
Investment in shares	102.98	(173.26)
Net cash inflow (outflow) from investing activities	97.14	(179.10)
Cash flow from financing activities		
Proceeds/(repayment) of borrowings	15.91	(94.94)
Finance costs	-	(21.76)
Net cash inflow (outflow) from financing activities	15.91	(116.70)
Net increase (Decrease) in cash and cash equivalents	(437.90)	189.61
Cash and Cash equivalents at the beginning of the Year	931.38	741.77
Cash and Cash equivalents at the end of the Year	493.48	931.38

For and on behalf of the Board

Sushant Mohan Lal
Executive whole time director
DIN: 01227151Place: Hyderabad
Date: 14.11.2024



Ramanatham & Rao
Chartered Accountants


P. B. No. 2102, Flat # 302, Kala Mansion,
Sarojini Devi Road, Secunderabad - 500 003
www.ramanathamand Rao.in
mail@ramanathamand Rao.in
ramanathamand Rao@gmail.com
040- 27814147, 27849305, 27840307

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 30th September, 2024 and year to date results for the period 1st April, 2024 to 30th September, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)


K.Sreenivasan

Partner
Membership No.206421

UDIN: 24206421BKAKNQ3906

Place : Secunderabad

Date : 14.11.2024





**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

Review Report to The Board of Directors

Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30th September, 2024 and year to date results for the period 1st April, 2024 to 30th September, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11th July, 2023 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable
4. The Statement includes the results of the subsidiary Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain.



Ramanatham & Rao


Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total assets of of Rs. 2146.51 Lakhs as at 30th September, 2024, total revenues of Rs 588.61lakhs and Rs. 1310.01 lakhs, total net profit after tax of Rs(127.17) lakhs and Rs. (19.43) lakhs, total comprehensive Income of Rs(98.91) lakhs and Rs. (14.75) lakhs for the quarter ended 30th September, 2024 and for the period from 1st April, 2024 to 30th September, 2024 respectively and net cash outflows of Rs436.77 Lakhs for the period from 1st April, 2024 to 30th September, 2024 as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan
Partner
Membership No.206421

UDIN: 24206421BKAKNR3794
Place : Secunderabad
Date : 14.11.2024

